Perimenopause and Menopause: A Naturopathic Evidence Review

Educational disclaimer: This article is written for healthcare practitioners and informed readers seeking to understand the evidence base for naturopathic approaches to perimenopause and menopause. It does not constitute medical advice. Menopausal symptom management, and any decision about hormone therapy, should be made individually with a qualified practitioner. This article does not diagnose or treat any condition.

Why This Review Now

On 10 November 2025, the FDA announced it was removing the broad boxed warnings for cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy (MHT) product labelling, following a review of the accumulated trial evidence and an expert panel. The agency is retaining the boxed warning on endometrial cancer risk for oestrogen-alone products in women with a uterus. This is a genuine shift from the labelling introduced in the early 2000s in response to the Women's Health Initiative (WHI) findings, and it will change how many women and prescribers weigh hormone therapy against natural approaches.

That regulatory change does not, on its own, make hormone therapy the right choice for every patient, and it does not make the evidence for natural interventions any stronger or weaker than it was the week before. What it does is raise the stakes on giving patients an honest, evidence-graded picture of what natural approaches to perimenopause and menopause can and cannot do, rather than a menu of supplements presented as broadly equivalent. That is the purpose of this review.

The Transition in Brief

Perimenopause is the transition period, typically beginning in the mid-to-late 40s and lasting several years, during which ovarian follicle depletion produces increasingly erratic oestradiol and progesterone secretion before the final menstrual period. Progesterone production tends to decline earlier and more steeply than oestradiol as anovulatory cycles become more frequent, which is why perimenopausal women can present with relative oestrogen dominance symptoms (heavy bleeding, breast tenderness, worsening premenstrual symptoms) even as their overall reproductive hormone output is falling. The mechanics of this ratio imbalance, and the DUTCH testing and dietary and herbal strategies used to address it, are covered in detail in the estrogen dominance naturopathic protocol.

Menopause itself is defined retrospectively as twelve consecutive months without a menstrual period, at a median age of 51 in Western populations, after which oestradiol settles at a low, stable postmenopausal level. Vasomotor symptoms (hot flushes and night sweats), sleep disruption, mood changes, vaginal dryness, and joint aches are the most commonly reported symptoms across the transition, with substantial individual variation in severity and duration.

Thyroid dysfunction and HPA axis dysregulation both overlap heavily with the perimenopausal symptom picture, fatigue, weight change, mood disturbance, and sleep disruption are common to all three, and a thorough naturopathic assessment should not default to attributing every symptom to reproductive hormone change without excluding these confounders. Where fatigue, temperature intolerance, or unexplained weight change are prominent, the Hashimoto's thyroiditis root cause guide outlines the relevant thyroid workup, and functional hormone mapping (oestrogen metabolites, progesterone metabolites, and the cortisol curve) is described in the DUTCH test guide.

Grading the Evidence: What Actually Works, and How Well

Naturopathic and complementary approaches to menopausal symptoms are used by an estimated 40 to 50 percent of women in Western countries, a figure cited in the introduction to the largest meta-analysis of plant-based menopause therapies published to date. The honest answer to "does it work" varies substantially by intervention, and the strength of that evidence has shifted over the past decade as larger pooled analyses have superseded smaller, more heterogeneous trials.

Phytoestrogens (Soy Isoflavones, Red Clover): Modest and Real, But Inconsistent

Phytoestrogens are plant-derived compounds, principally soy isoflavones (genistein, daidzein) and red clover isoflavones, that bind weakly to oestrogen receptors, preferentially the beta subtype expressed in vasomotor and bone tissue.

The 2013 Cochrane review of phytoestrogens for vasomotor symptoms (Lethaby et al., 43 trials, 4,084 women) found that while some trials showed benefit over placebo, the trial evidence was too heterogeneous and generally too high-risk-of-bias to draw a firm conclusion, and the authors described the placebo response itself as substantial and highly variable across trials (reductions in flush frequency of 1 to 59 percent on placebo alone). This review left practitioners with a genuinely inconclusive picture.

A larger and more recent synthesis has since narrowed that uncertainty somewhat. Franco et al.'s 2016 meta-analysis in JAMA (62 trials, 6,653 women) found that phytoestrogen use as a category was associated with a statistically significant reduction in daily hot flush frequency (pooled mean difference -1.31 flushes per day) and in vaginal dryness score, though not in night sweat frequency. Dietary and supplemental soy isoflavones specifically showed a smaller but still significant effect on hot flush frequency. The authors were explicit that 74 percent of the included trials carried a high risk of bias in three or more domains, so the honest clinical summary is: a modest, statistically real reduction in hot flush frequency at the group level, most consistent for soy isoflavones, built on a trial base that remains methodologically weak.

Clinical translation: Phytoestrogens are a reasonable, low-risk option to trial for mild to moderate vasomotor symptoms, with effect sizes that patients should be told are modest, not comparable to hormone therapy, and not reliably reproduced across all trials.

Black Cohosh: Popular, But the Best Evidence Does Not Support It

Black cohosh (Actaea racemosa, syn. Cimicifuga racemosa) is the most widely used single herbal medicine for menopausal symptoms, and it is also the clearest example in this review of a mismatch between popularity and trial evidence.

The 2012 Cochrane review (Leach and Moore, 16 trials, 2,027 women, median dose 40 mg/day, mean duration 23 weeks) found no significant difference between black cohosh and placebo in daily hot flush frequency (mean difference 0.07 flushes/day, 95% CI -0.43 to 0.56, P=0.79) or in composite menopausal symptom scores (P=0.34). Where black cohosh was compared directly against hormone therapy, hormone therapy produced significantly greater reductions in both hot flush frequency and symptom scores. The review authors noted substantial heterogeneity across the underlying trials and urged caution in interpretation, but their headline finding stands: on the pooled RCT evidence, black cohosh has not demonstrated efficacy over placebo for vasomotor symptoms.

This does not necessarily mean black cohosh has zero biological activity, mechanistic and animal data suggest possible dopaminergic and serotonergic activity distinct from oestrogen receptor binding, but it does mean that the strongest clinical trial evidence available does not support the efficacy claims commonly attached to it in retail marketing. NCCIH's evidence summary reaches a similarly cautious conclusion, describing the evidence for black cohosh as mixed and inconclusive overall.

Clinical translation: Black cohosh should not be presented to patients as an established, evidence-backed alternative to hormone therapy. If a patient wants to trial it given its generally favourable safety profile in short-term use, that is a reasonable shared decision, but the honest framing is "weak and inconsistent evidence, not proven ineffective, but not proven effective either."

Evening Primrose Oil: Individual Trials Are Mixed, Pooled Evidence Is Not Supportive

Evening primrose oil is frequently recommended for hot flushes despite a comparatively thin evidence base. A representative small trial (Farzaneh et al., 2013, 56 women, 6 weeks, 500 mg twice daily versus placebo) found a statistically significant improvement in hot flush severity and in several quality-of-life subscales relative to placebo, but no significant between-group difference in flush frequency, the more commonly used primary outcome in this literature. Pooled analyses of the available small trials have generally found no consistent, clinically meaningful effect on hot flush frequency across the evidence base as a whole.

Clinical translation: The evidence for evening primrose oil in vasomotor symptoms is weaker and more inconsistent than for phytoestrogens, and it should not be positioned as a first-line recommendation.

Exercise: Improves Symptom Severity, Does Not Match Hormone Therapy

The 2014 Cochrane review of exercise for vasomotor menopausal symptoms (Daley et al., 21 trials, 2,884 women) is one of the more clinically useful reviews in this space because it compares exercise against genuinely relevant alternatives. Exercise significantly improved vasomotor symptom severity compared with no treatment, but one included trial found hormone therapy more effective than exercise, and the review authors concluded there was insufficient evidence to establish how exercise compares with hormone therapy or yoga more broadly, given the small number of trials making each specific comparison.

Clinical translation: Regular exercise (both aerobic and resistance training) is a reasonable, near-zero-risk, multi-benefit recommendation for every perimenopausal and menopausal patient regardless of vasomotor symptom severity, given its independent cardiometabolic and bone benefits, but it should not be oversold as a replacement for hormone therapy in women with severe symptoms.

Cognitive Behavioural Therapy: The Best-Evidenced Non-Hormonal Option for Symptom Burden

Cognitive behavioural therapy (CBT) is less commonly discussed in naturopathic literature than herbal or nutritional interventions, but it has some of the more consistent RCT support in this entire review. The MENOS 2 trial (Ayers et al., 2012, 140 women with 10 or more problematic hot flushes/night sweats weekly) found that both group and guided self-help CBT produced significant, sustained reductions in hot flush and night sweat problem ratings at 6 and 26 weeks compared with no-treatment controls, along with improvements in mood and quality of life. The 2023 North American Menopause Society nonhormone therapy position statement lists CBT and clinical hypnosis among the interventions with the strongest evidence base for nonhormonal vasomotor symptom management, ranking them above most dietary supplements reviewed in the same statement.

Clinical translation: CBT deserves a more prominent place in naturopathic and integrative menopause protocols than it typically receives. It is low-risk, addresses the symptom burden (not just the physiological frequency of flushes), and has a more consistent trial base than most herbal options covered above.

Where Hormone Therapy Still Leads, and Why the Label Change Matters

Across nearly every direct comparison in the trials reviewed above, including black cohosh and exercise, hormone therapy produced a larger reduction in vasomotor symptom frequency and severity than the natural comparator. This is not a controversial finding; it is consistent with decades of endocrinology and was never seriously disputed even during the years when MHT prescribing fell sharply following the 2002 WHI report that estrogen plus progestin therapy increased risk of breast cancer, coronary events, and stroke in the trial population of postmenopausal women, a finding that led to the original boxed warning.

The nuance that the original 2002 WHI reporting under-communicated, and that subsequent re-analysis by age and time-since-menopause has clarified, is that absolute risk varies substantially by age at initiation and formulation. The FDA's November 2025 label change reflects that re-analysis; it is a regulatory correction based on accumulated evidence, not a reversal of the underlying safety data. For naturopathic practitioners, the practical implication is that hormone therapy is now a more clearly available, and for many patients a more clearly appropriate, option than the 2003-era labelling implied, and natural approaches should be positioned honestly as complementary or alternative options for patients who cannot or choose not to use hormone therapy, not as equivalent substitutes with comparable efficacy.

A Caution on "Bioidentical" Marketing Claims

Patients frequently ask about compounded "bioidentical" hormone preparations, marketed as more natural and safer than FDA-approved hormone therapy. The American College of Obstetricians and Gynecologists' 2023 clinical consensus on compounded bioidentical menopausal hormone therapy states plainly that evidence to support marketing claims of superior safety or effectiveness for compounded preparations is lacking, and recommends FDA-approved menopausal hormone therapies (which include plant-derived, molecularly identical oestradiol and micronised progesterone formulations) over custom-compounded products where an FDA-approved option exists. This distinction matters clinically: "bioidentical" as a marketing term for compounded products is not the same claim as the FDA-approved bioidentical formulations already available on prescription, and naturopathic practitioners advising patients on hormone options should be clear about which category a given product falls into.

Practical Assessment Framework

A naturopathic approach to perimenopause and menopause should not begin with a supplement list. It should begin with assessment:

1. Rule out or characterise thyroid overlap. A full thyroid panel (TSH, free T3, free T4, TPO antibodies) distinguishes thyroid-driven fatigue and weight change from the menopausal transition itself, detailed in the Hashimoto's protocol.
2. Map the hormonal picture where indicated, particularly in perimenopause where cycle irregularity makes single-point serum testing hard to interpret. The DUTCH test guide covers cortisol pattern, oestrogen metabolite, and progesterone metabolite mapping relevant to this transition.
3. Discuss hormone therapy honestly, including the November 2025 labelling change, as a genuine option for patients with moderate to severe symptoms, rather than a last resort.
4. Grade natural options by the evidence above rather than by popularity: CBT and exercise carry the most consistent support for symptom burden; phytoestrogens (particularly soy isoflavones) have modest, real, but methodologically weak support for hot flush frequency; black cohosh and evening primrose oil have the least support of the commonly recommended options.
5. Address sleep, mood, and stress physiology directly. HPA axis support is relevant here; the mechanisms and RCT evidence for cortisol and sleep are covered in the ashwagandha clinical evidence review.
6. Reassess at 8 to 12 weeks for any intervention trialled, using a simple symptom frequency and severity diary, and escalate to hormone therapy discussion if natural approaches are not providing adequate relief.

Frequently Asked Questions

Is black cohosh worth trying at all?

The best pooled trial evidence (Cochrane, 2012) found no significant benefit over placebo for hot flush frequency or menopausal symptom scores. It is not established as harmful in short-term use, and some patients report subjective benefit, but practitioners should not present it as an evidence-backed alternative to hormone therapy, and should set expectations accordingly if a patient chooses to trial it.

Do soy isoflavones actually reduce hot flushes?

The largest available meta-analysis (Franco et al., JAMA 2016) found a statistically significant, modest reduction in hot flush frequency with phytoestrogen use, largest for dietary and supplemental soy isoflavones. The effect size is real but small compared with hormone therapy, and the majority of underlying trials carried meaningful risk of bias.

Does the FDA's 2025 label change mean hormone therapy has no risks?

No. The FDA is removing the broad boxed warnings for cardiovascular disease, breast cancer, and probable dementia based on a re-analysis of the evidence by age and time since menopause, but it is retaining the boxed warning on endometrial cancer risk for oestrogen-alone therapy in women with a uterus. Hormone therapy still carries individualised risks and benefits that should be discussed with a prescribing practitioner, not treated as risk-free.

What has the best evidence for hot flushes among non-hormonal options?

Across the trials reviewed here, CBT and structured exercise have the most consistent RCT support for reducing symptom severity and burden, ahead of the commonly recommended herbal options.

Key Clinical Takeaways

1. The FDA removed the broad boxed warnings (cardiovascular disease, breast cancer, probable dementia) from menopausal hormone therapy labelling in November 2025, while retaining the endometrial cancer warning for oestrogen-alone products, a meaningful regulatory shift that should inform how natural options are framed against hormone therapy.
2. Phytoestrogens, particularly soy isoflavones, have modest but statistically real support for reducing hot flush frequency in the largest available meta-analysis, built on a trial base with substantial risk of bias.
3. Black cohosh, despite its popularity, showed no significant benefit over placebo in the 2012 Cochrane review's pooled analysis of 16 RCTs.
4. Evening primrose oil has weak, inconsistent trial support and should not be a first-line recommendation.
5. Exercise and CBT have the most consistent evidence among non-hormonal options for reducing symptom severity and burden, and deserve a more central place in naturopathic protocols than they typically receive.
6. Hormone therapy remains more effective than any natural intervention reviewed here in direct trial comparisons; naturopathic care should position itself as complementary or alternative for appropriate patients, not as an equivalent substitute.
7. Compounded "bioidentical" hormone products marketed as safer than FDA-approved hormone therapy lack evidence to support those specific marketing claims, per the 2023 ACOG clinical consensus.
8. Thyroid dysfunction and HPA axis dysregulation overlap substantially with the perimenopausal symptom picture and should be assessed before symptoms are attributed to reproductive hormone change alone.

Key References

• FDA. "HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy." Press announcement, 10 November 2025.
• Franco OH, Chowdhury R, Troup J, et al. "Use of Plant-Based Therapies and Menopausal Symptoms: A Systematic Review and Meta-analysis." JAMA 2016; 315(23):2554-2563. PMID 27327802.
• Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. "Phytoestrogens for menopausal vasomotor symptoms." Cochrane Database of Systematic Reviews 2013; (12):CD001395. PMID 24323914.
• Leach MJ, Moore V. "Black cohosh (Cimicifuga spp.) for menopausal symptoms." Cochrane Database of Systematic Reviews 2012; (9):CD007244. PMID 22972105.
• Daley A, Stokes-Lampard H, Thomas A, MacArthur C. "Exercise for vasomotor menopausal symptoms." Cochrane Database of Systematic Reviews 2014; (11):CD006108. PMID 25431132.
• Ayers B, Smith M, Hellier J, Mann E, Hunter MS. "Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial." Menopause 2012; 19(7):749-759. PMID 22336748.
• Farzaneh F, Fatehi S, Sohrabi MR, Alizadeh K. "The effect of oral evening primrose oil on menopausal hot flashes: a randomized clinical trial." Archives of Gynecology and Obstetrics 2013; 288(5):1075-1079. PMID 23625331.
• Shufelt CL, Brown V, Carpenter JS, et al. "The 2023 nonhormone therapy position statement of The North American Menopause Society." Menopause 2023; 30(6):573-590. PMID 37252752.
• Rossouw JE, Anderson GL, Prentice RL, et al. "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial." JAMA 2002; 288(3):321-333. PMID 12117397.
• American College of Obstetricians and Gynecologists. "Compounded Bioidentical Menopausal Hormone Therapy: ACOG Clinical Consensus No. 6." Obstetrics and Gynecology 2023; 142(5):1266-1273. PMID 37856860.